公开(公告)号：US20220233706A1

公开(公告)日：2022-07-28

申请号：US17531199

申请日：2021-11-19

申请人： ANTIKOR BIOPHARMA LIMITED

发明人： Mahendra Persaud Deonarain ,  Gokhan Yahioglu ,  Ioanna Stamati ,  Savvas Saouros ,  Prashant Bhimrao Kapadnis

IPC分类号： A61K47/68

摘要： The invention provides compounds comprising a therapeutic agent coupled to a carrier molecule, with a minimum coupling ratio of 5:1; wherein the carrier molecule is (i) an antibody fragment or derivative thereof or (ii) an antibody mimetic or derivative thereof; and wherein the therapeutic agents are coupled onto a lysine amino acid residue; and further wherein the therapeutic agent is not a photosensitising agent. There is also provided uses, methods relating to such compounds, as well as processes for their manufacture.

公开(公告)号：US11202837B2

公开(公告)日：2021-12-21

申请号：US15513393

申请日：2015-09-25

申请人： Antikor Biopharma Limited

发明人： Mahendra Persaud Deonarain ,  Gokhan Yahioglu ,  Ioanna Stamati ,  Savvas Saouros ,  Prashant Bhimrao Kapadnis

IPC分类号： A61K47/64 ,  A61K47/68 ,  A61K47/00 ,  C07K16/00

摘要： The invention provides compounds comprising a therapeutic agent coupled to a carrier molecule, with a minimum coupling ratio of 5:1; wherein the carrier molecule is (i) an antibody fragment or derivative thereof or (ii) an antibody mimetic or derivative thereof; and wherein the therapeutic agents are coupled onto a lysine amino acid residue; and further wherein the therapeutic agent is not a photosensitising agent. There is also provided uses, methods relating to such compounds, as well as processes for their manufacture.

公开(公告)号：US20170360951A1

公开(公告)日：2017-12-21

申请号：US15513393

申请日：2015-09-25

申请人： Antikor Biopharma Limited

发明人： Mahendra Persaud Deonarain ,  Gokhan Yahioglu ,  Ioanna Stamati ,  Savvas Saouros ,  Prashant Bhimrao Kapadnis

IPC分类号： A61K47/68 ,  A61K47/00 ,  C07K16/00

CPC分类号： A61K47/6803 ,  A61K47/00 ,  A61K47/6809 ,  A61K47/6855 ,  C07K16/00 ,  C07K2317/92

摘要： The invention provides compounds comprising a therapeutic agent coupled to a carrier molecule, with a minimum coupling ratio of 5:1; wherein the carrier molecule is (i) an antibody fragment or derivative thereof or (ii) an antibody mimetic or derivative thereof; and wherein the therapeutic agents are coupled onto a lysine amino acid residue; and further wherein the therapeutic agent is not a photosensitising agent. There is also provided uses, methods relating to such compounds, as well as processes for their manufacture.